Combined modality treatment for patients with stage IV melanoma: Cyclophosphamide and a dendritic cell vaccine loaded with killed allogeneic melanoma cells.

Trial Profile

Combined modality treatment for patients with stage IV melanoma: Cyclophosphamide and a dendritic cell vaccine loaded with killed allogeneic melanoma cells.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Cyclophosphamide (Primary) ; Dendritic cell vaccine-SBI Biotech (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 May 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 17 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 16 Jul 2011 Actual initiation date (Jul 2011) added as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top